Use of peripheral neuromodulation of the S3 region for treatment of detrusor overactivity: a urodynamic-based study

Role of percutaneous posterior tibial nerve stimulation either alone or combined with an anticholinergic agent in treating patients with overactive bladder

“…[19] In a randomized, controlled study, Finazzi-Agro et al [17] reported that PTNS significantly increased voided volume than sham treatment (150-186 mL in the PTNS treatment group vs. 146-150 mL in the sham group, p<0.001). In a urodynamic study, Klingler et al [21] reported that PTNS increased the mean total bladder capacity from 197 mL at baseline (range 35-349 mL) to 252 mL (range 78-384 mL, p<0.01) after 12 weeks of therapy. When PTNS was compared with tolterodine extended release in the OrBIT study, both therapies demonstrated statistically significant improvements in incontinence episodes, voids per day, and nocturia.…”

Toe Spreading Ability in Men With Chronic Pelvic Pain Syndrome

“…The sural nerve originates from the union of the medial sural cutaneous branch of the tibial nerve and the sural communicating branch of the common peroneal nerve. Treating certain bladder dysfunctions by afferent nerve neuromodulation techniques such as sural nerve stimulation is another example of neural intimacy and the central association between lower extremity and pelvic visceral functions [18]. Percutaneous tibial nerve stimulation has also been successfully used in the neuromodulative treatment of CPPS as well as overactive bladder [19,20].…”

Neuromodulation in Management of Overactive Bladder

“…Klingler et al demonstrated reduction in pain and urodynamic improvement of DI, total bladder capacity, first bladder sensation, bladder volume at normal desire to void, and urinary frequency (Klingler et al, 2000). Peters et al demonstrated the objective effectiveness of PTNS in OAB symptoms compared to extendedrelease tolterodine (Peters et al, 2009).…”